These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38652656)

  • 1. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
    Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T; Ekholm E; Johnsson E; Garcia-Sanchez R; Dronamraju N; Jabbour SA; Lind M
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
    Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S; Deng X; Ma Y; Li Z; Wang Y; Wang Y
    Appl Health Econ Health Policy; 2021 Jan; 19(1):69-79. PubMed ID: 32783086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
    Hansen L; Iqbal N; Ekholm E; Cook W; Hirshberg B
    Endocr Pract; 2014 Nov; 20(11):1187-97. PubMed ID: 25370334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
    Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
    Sjöstrand M; Iqbal N; Lu J; Hirshberg B
    Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Frías JP; Maaske J; Suchower L; Johansson L; Hockings PD; Iqbal N; Wilding JPH
    Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
    Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.